[go: up one dir, main page]

WO2025072797A3 - Immunogens and vaccine compositions against hiv - Google Patents

Immunogens and vaccine compositions against hiv Download PDF

Info

Publication number
WO2025072797A3
WO2025072797A3 PCT/US2024/049021 US2024049021W WO2025072797A3 WO 2025072797 A3 WO2025072797 A3 WO 2025072797A3 US 2024049021 W US2024049021 W US 2024049021W WO 2025072797 A3 WO2025072797 A3 WO 2025072797A3
Authority
WO
WIPO (PCT)
Prior art keywords
against hiv
hiv
immunogens
vaccine compositions
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/049021
Other languages
French (fr)
Other versions
WO2025072797A2 (en
Inventor
Morgane Marie ROLLAND
Eric LEWITUS
Hongjun BAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of WO2025072797A2 publication Critical patent/WO2025072797A2/en
Publication of WO2025072797A3 publication Critical patent/WO2025072797A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein Arc modified HIV-1 Env polypeptides comprising at least one modified hypervariable loop and isolated polynucleotides comprising a nucleotide sequence that encodes the modified HIV-1 Env polypeptides. Also disclosed herein are vaccine or immunogenic compositions for inducing an immune response in a subject against HIV, as well as a method of inducing an immune response against HIV in a subject. Further disclosed herein are methods of identifying an antibody against HIV in a sample.
PCT/US2024/049021 2023-09-27 2024-09-27 Immunogens and vaccine compositions against hiv Pending WO2025072797A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363585686P 2023-09-27 2023-09-27
US63/585,686 2023-09-27

Publications (2)

Publication Number Publication Date
WO2025072797A2 WO2025072797A2 (en) 2025-04-03
WO2025072797A3 true WO2025072797A3 (en) 2025-05-15

Family

ID=95201347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/049021 Pending WO2025072797A2 (en) 2023-09-27 2024-09-27 Immunogens and vaccine compositions against hiv

Country Status (1)

Country Link
WO (1) WO2025072797A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028625A2 (en) * 2003-09-17 2005-03-31 Duke University Consensus/ancestral immunogens
US20190194262A1 (en) * 2011-10-12 2019-06-27 University Of Washington, Center For Commercialization Engineered outer domain (eod) of hiv gp120 and mutants thereof
US20210277065A1 (en) * 2016-03-01 2021-09-09 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028625A2 (en) * 2003-09-17 2005-03-31 Duke University Consensus/ancestral immunogens
US20190194262A1 (en) * 2011-10-12 2019-06-27 University Of Washington, Center For Commercialization Engineered outer domain (eod) of hiv gp120 and mutants thereof
US20210277065A1 (en) * 2016-03-01 2021-09-09 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies

Also Published As

Publication number Publication date
WO2025072797A2 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
CA2733898C (en) Mosaic clade m env-based polyvalent hiv vaccine
US9011875B2 (en) Human immunodeficiency virus type 1 clade M mosaic gag polypeptides
EP2371387A3 (en) HIV consensus sequence antigens and their use in vaccina
TW200621806A (en) Vaccine
del Moral-Sánchez et al. Strategies for inducing effective neutralizing antibody responses against HIV-1
WO2008140579A3 (en) Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
Lema et al. HIV vaccines: A brief overview
PT1159298E (en) Hiv peptides, antigens and vaccine compositions
BRAND et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
EP1921146B1 (en) Recombinant vectors based on the modified ankara virus (mva) as preventive and therapeutic vaccines against aids
Leung et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins
Stuart et al. Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea
WO2025072797A3 (en) Immunogens and vaccine compositions against hiv
WO2023192971A3 (en) Immunogens and vaccine compositions against hiv
WO2001070262A3 (en) A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
WO2005027844A3 (en) Dna vaccine compositions and methods of use
Pahar et al. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
Iglesias et al. Chimeric proteins containing HIV-1 T cell epitopes: Expression in E. coli, purification and induction of antibodies in mice
WO2006091455A3 (en) Molecular scaffolds for hiv-1 immunogens
SIV Recombinant Modified Vaccinia Virus
WO2007070501A3 (en) A vaccination method
BRUNET et al. Comparative Analysis of Humoral Immune Responses to HIV Type Envelope Glycoproteins in Mice Immunized with DNA Vaccine, Recombinant Semliki Forest Virus RNA, or Recombinant Semliki Forest Virus Particles
Chege Pre-clinical assessment of novel candidate HIV-1 vaccines using the Chacma baboon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24873743

Country of ref document: EP

Kind code of ref document: A2